M Afshar1, A D Martinez, R L Gallo, T R Hata. 1. Division of Dermatology, Department of Medicine, University of California, San Diego, USA. maafshar@ucsd.edu
Abstract
BACKGROUND: Interferon-alpha (IFN-α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis C patients treated with IFN-α is increasingly recognized, but the distinct associated features, aetiology and management have not been reviewed. OBJECTIVE: To review all published cases of hepatitis C patients who developed psoriasis while receiving IFN-α therapy. METHODS: The review was conducted by searching the PubMed database using the keywords 'hepatitis C' AND 'psoriasis.' In addition, references to additional publications not indexed for PubMed were followed to obtain a complete record of published data. RESULTS: We identified 32 publications describing 36 subjects who developed a psoriatic eruption while receiving IFN-α therapy for hepatitis C. Topical therapies were a commonly employed treatment modality, but led to resolution in only 30% of cases in which they were employed solely. Cessation of IFN-α therapy led to resolution in 93% of cases. Hundred per cent of those who developed psoriasis while on IFN-α therapy responded to systemic therapy and were able to continue the drug. CONCLUSION: Further studies and analysis of IFN-α-induced lesions are necessary to clarify the role of IFN-α and the hepatitis C virus in the development of psoriatic lesions.
BACKGROUND:Interferon-alpha (IFN-α) therapy is used to treat hepatitis C infection. The exacerbation and occurrence of psoriasis in hepatitis Cpatients treated with IFN-α is increasingly recognized, but the distinct associated features, aetiology and management have not been reviewed. OBJECTIVE: To review all published cases of hepatitis Cpatients who developed psoriasis while receiving IFN-α therapy. METHODS: The review was conducted by searching the PubMed database using the keywords 'hepatitis C' AND 'psoriasis.' In addition, references to additional publications not indexed for PubMed were followed to obtain a complete record of published data. RESULTS: We identified 32 publications describing 36 subjects who developed a psoriatic eruption while receiving IFN-α therapy for hepatitis C. Topical therapies were a commonly employed treatment modality, but led to resolution in only 30% of cases in which they were employed solely. Cessation of IFN-α therapy led to resolution in 93% of cases. Hundred per cent of those who developed psoriasis while on IFN-α therapy responded to systemic therapy and were able to continue the drug. CONCLUSION: Further studies and analysis of IFN-α-induced lesions are necessary to clarify the role of IFN-α and the hepatitis C virus in the development of psoriatic lesions.
Authors: Robert Bissonnette; Kim Papp; Catherine Maari; Yihong Yao; Gabriel Robbie; Wendy I White; Chenxiong Le; Barbara White Journal: J Am Acad Dermatol Date: 2010-03 Impact factor: 11.527
Authors: Yihong Yao; Laura Richman; Chris Morehouse; Melissa de los Reyes; Brandon W Higgs; Anmarie Boutrin; Barbara White; Anthony Coyle; James Krueger; Peter A Kiener; Bahija Jallal Journal: PLoS One Date: 2008-07-16 Impact factor: 3.240
Authors: Jun Gui; Michael Gober; Xiaoping Yang; Kanstantsin V Katlinski; Christine M Marshall; Meena Sharma; Victoria P Werth; Darren P Baker; Hallgeir Rui; John T Seykora; Serge Y Fuchs Journal: J Invest Dermatol Date: 2016-06-29 Impact factor: 8.551
Authors: Fiona Semple; Heather MacPherson; Sheila Webb; Fiona Kilanowski; Laura Lettice; Sarah L McGlasson; Ann P Wheeler; Valerie Chen; Glenn L Millhauser; Lauren Melrose; Donald J Davidson; Julia R Dorin Journal: PLoS Genet Date: 2015-12-08 Impact factor: 5.917